Why the study?
What is the mechanism linking hypertriglyceridemia to coronary heart disease, and what are the implications for appropriate lipid-lowering therapy?
Population
Patients with coronary heart disease and hypertriglyceridemia
Design
Review
Authors
Loading...
Mechanism uncertainty precludes firm hypertriglyceridemia therapy choice; leaves open whether statins or niacin/fibrates are preferred.
What is the mechanism linking hypertriglyceridemia to coronary heart disease, and what are the implications for appropriate lipid-lowering therapy?
Understanding the exact mechanism linking hypertriglyceridemia to coronary heart disease is crucial for selecting the most appropriate lipid-lowering therapy.
S. M. Grundy (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: